MA51681A - Anticorps humains contre l'hémagglutinine de la grippe - Google Patents

Anticorps humains contre l'hémagglutinine de la grippe

Info

Publication number
MA51681A
MA51681A MA051681A MA51681A MA51681A MA 51681 A MA51681 A MA 51681A MA 051681 A MA051681 A MA 051681A MA 51681 A MA51681 A MA 51681A MA 51681 A MA51681 A MA 51681A
Authority
MA
Morocco
Prior art keywords
human antibodies
antibodies against
influenza hemagglutinin
against influenza
hemagglutinin
Prior art date
Application number
MA051681A
Other languages
English (en)
French (fr)
Inventor
William Olson
Lisa A Purcell
Jonathan Viau
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA51681A publication Critical patent/MA51681A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA051681A 2018-01-26 2019-01-24 Anticorps humains contre l'hémagglutinine de la grippe MA51681A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862622480P 2018-01-26 2018-01-26

Publications (1)

Publication Number Publication Date
MA51681A true MA51681A (fr) 2021-05-05

Family

ID=66286952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051681A MA51681A (fr) 2018-01-26 2019-01-24 Anticorps humains contre l'hémagglutinine de la grippe

Country Status (17)

Country Link
US (1) US11780907B2 (cg-RX-API-DMAC7.html)
EP (1) EP3743442A1 (cg-RX-API-DMAC7.html)
JP (2) JP7372925B2 (cg-RX-API-DMAC7.html)
KR (1) KR102820941B1 (cg-RX-API-DMAC7.html)
CN (1) CN111670195B (cg-RX-API-DMAC7.html)
AU (1) AU2019212480B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020014849A2 (cg-RX-API-DMAC7.html)
CA (1) CA3088194A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020001884A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020009043A2 (cg-RX-API-DMAC7.html)
EA (1) EA202091563A1 (cg-RX-API-DMAC7.html)
IL (1) IL275884B2 (cg-RX-API-DMAC7.html)
MA (1) MA51681A (cg-RX-API-DMAC7.html)
MX (1) MX2020007772A (cg-RX-API-DMAC7.html)
PH (1) PH12020551051A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006379UA (cg-RX-API-DMAC7.html)
WO (1) WO2019147867A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7611908B2 (ja) * 2019-10-28 2025-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗血球凝集素抗体およびその使用方法
WO2021202235A1 (en) * 2020-04-01 2021-10-07 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
KR20230135569A (ko) * 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
EP4508077A4 (en) 2022-04-14 2026-03-25 Invisishield Tech Ltd COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
KR102835659B1 (ko) * 2024-11-28 2025-07-24 주식회사 마크헬츠 인플루엔자 a형 바이러스 검출용 항체 및 이의 용도

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
JP2008539785A (ja) * 2005-05-16 2008-11-20 モルフォテック、インク. 所望の表現型を示す細胞を選択するために制御されたベクター
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP1947423A1 (en) 2007-01-16 2008-07-23 Sony Deutschland Gmbh Distance, orientation and velocity sensitive controller
JP5597128B2 (ja) 2007-05-11 2014-10-01 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド H5トリインフルエンザの診断および監視に有用なh5亜型特異的結合タンパク質
US8383121B2 (en) 2007-09-13 2013-02-26 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
JP5490695B2 (ja) 2007-09-13 2014-05-14 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド インフルエンザウイルスh5亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
JP5490725B2 (ja) 2008-02-05 2014-05-14 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド H5亜型インフルエンザウイルスの普遍的な検出のための結合タンパク質およびエピトープブロッキングelisa
CA2719201A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
AU2008365616A1 (en) 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
KR101790354B1 (ko) 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 h3n2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
CN102791734B (zh) 2010-03-08 2014-10-15 赛特瑞恩股份有限公司 源自人b细胞且具有抗甲型流感病毒的中和活性的人单克隆抗体
RU2635999C2 (ru) 2010-06-17 2017-11-17 ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи Антитела, подходящие для пассивной иммунизации против гриппа
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
ITRM20110606A1 (it) 2011-11-16 2013-05-17 Ist Superiore Sanita Peptidi della lattoferrina per lo uso come inibitori ad ampio spettro dellainfezione da virus della influenza.
WO2013081463A2 (en) 2011-12-02 2013-06-06 Aimm Therapeutics B.V. Influenza a virus specific antibodies
MX367743B (es) 2011-12-05 2019-09-04 Trellis Bioscience Llc Anticuerpos utiles para la inmunizacion pasiva de influenza.
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
BR112015010817A8 (pt) 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 a 바이러스 중화 결합 분자를 포함하는 조성물
SG11201602522VA (en) * 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
AU2015214146B2 (en) 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
MX2016012530A (es) 2014-03-27 2017-01-05 Genentech Inc Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso.
CN104031118B (zh) 2014-06-19 2016-04-13 天津大学 鼠多瘤病毒衣壳粒的新型亲和肽配基及其设计筛选方法
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10435462B2 (en) 2015-03-31 2019-10-08 Viro Dynamics Corporation Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
WO2020221450A1 (en) 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection

Also Published As

Publication number Publication date
EA202091563A1 (ru) 2020-10-08
JP7372925B2 (ja) 2023-11-01
KR20200115517A (ko) 2020-10-07
JP2023060018A (ja) 2023-04-27
AU2019212480B2 (en) 2025-07-24
WO2019147867A1 (en) 2019-08-01
JP2021511043A (ja) 2021-05-06
EP3743442A1 (en) 2020-12-02
CL2020001884A1 (es) 2020-12-11
CA3088194A1 (en) 2019-08-01
WO2019147867A9 (en) 2019-11-07
US20210371505A1 (en) 2021-12-02
MX2020007772A (es) 2020-09-18
AU2019212480A1 (en) 2020-09-10
IL275884A (en) 2020-08-31
PH12020551051A1 (en) 2021-08-23
IL275884B2 (en) 2024-11-01
US11780907B2 (en) 2023-10-10
CO2020009043A2 (es) 2020-07-31
KR102820941B1 (ko) 2025-06-16
BR112020014849A2 (pt) 2020-12-08
SG11202006379UA (en) 2020-07-29
IL275884B1 (en) 2024-07-01
CN111670195B (zh) 2024-08-13
CN111670195A (zh) 2020-09-15

Similar Documents

Publication Publication Date Title
MA49043A (fr) Formulation stable d'anticorps
EP3618871A4 (en) FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
EP3700416A4 (en) PRE-CONNECTED ANALYSIS SENSORS
EP3484518A4 (en) ANTIBODY ADJUVANCE CONJUGATES
EP3635724A4 (en) OBJECT TRACKING METHODS
MA43108A (fr) Anticorps neutralisant le virus syncytial respiratoire humain
MA54052A (fr) Formulation d'anticorps
MA51903A (fr) Formulations d'anticorps b7-h4
EP3618865A4 (en) HUMAN ANTI-SEMAPHORINE 4D ANTIBODY
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3496753A4 (en) PD-1 ANTIBODY FORMULATION
EP3807318A4 (en) MULTISPECIFIC ANTIBODY CONSTRUCTS
EP3814509A4 (en) INFLUENCE VIRUS HEMAGGLUTININ MUTANTS
MA54139A (fr) Formulation d'anticorps
EP3692072A4 (en) ANTI-HLA-DQ2.5 ANTIBODIES
EP3837286A4 (en) ANTIBODIES TO HUMAN ZNT8
MA55033A (fr) Formulation d'anticorps thérapeutique
EP3735987A4 (en) AMBANITIN ANTIBODY CONJUGATE
IL275884A (en) Human antibodies to influenza hemagglutinin
EP3849612A4 (en) ANTI-HIV ANTIBODIES 10-1074 VARIANTS
MA54097A (fr) Anticorps anti-fn14 humain
EP3885362A4 (en) ANTIBODY CONJUGATE
MA53466A (fr) Formulation stable d'anticorps anti-osmr
EP3342784A4 (en) COMPLETELY HUMAN ANTIBODY WITH SPECIFIC INHIBITION OF CONNEXIN 26
EP3833691A4 (en) HUMAN PD-L1 ANTIBODIES